missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. Novus Biologicals™ Plxdc2 Antibody (Fox Chase patent anti-TEM7R), Novus Biologicals™
  7. 30045872

Novus Biologicals™ Plxdc2 Antibody (Fox Chase patent anti-TEM7R), Novus Biologicals™

Human Monoclonal Antibody

Brand:  Novus Biologicals™ NBP3-28803-1mg

 View more versions of this product

Product Code. 30045872

  • € 920.00 / 1mg

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

Plxdc2 Monoclonal antibody specifically detects Plxdc2 in Human samples. It is validated for Flow Cytometry,ELISA,Functional Assay
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Plxdc2
Monoclonal
Unconjugated
Q6UX71
Human
Protein A purified
RUO
84898
Human
Purified
Flow Cytometry, ELISA, Functional Assay
Fox Chase patent anti-TEM7R
Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)
plexin domain containing 2,1200007L24Rik, plexin domain-containing protein 2, TEM7RFLJ14623, Tumor endothelial marker 7-related protein
TEM7R/ PLXDC2
1 mg
Primary
Reconstitute with sterile, distilled water to a final concentration of 1 mg/mL. Gently shake to solubilize completely. Do not vortex.
Store at -20°C in powder form. Store at -80°C once reconstituted.
IgG1
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.